SS18 and synovial sarcoma: Reminiscent of Ewing Sarcoma, TP53 mutations are rare events in synovial sarcomas (Table 1), suggesting that these cancers rely on the ability of the SS18-SSX fusion protein to abrogate the p53 response, facilitating oncogenic transformation in the presence of a functional, wild-type p53.